These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 35283385)

  • 1. Deterioration after Liver Transplantation and Transthyretin Stabilizer Administration in a Patient with ATTRv Amyloidosis with a Leu58Arg (p.Leu78Arg) TTR Variant.
    Hikishima S; Sakai K; Akagi A; Yamaguchi H; Shibata S; Hayashi K; Nakano H; Kanemoto M; Usui Y; Taniguchi Y; Komatsu J; Nakamura-Shindo K; Nozaki I; Hamaguchi T; Ono K; Iwasa K; Yamada M
    Intern Med; 2022 Aug; 61(15):2347-2351. PubMed ID: 35283385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hereditary Transthyretin Amyloidosis and the Impact of Classic and New Treatments on Kidney Function: A Review.
    Meléndrez-Balcázar E; Aranda-Vela K; Cervantes-Hernández A; López-Cureño S
    Am J Kidney Dis; 2024 Aug; 84(2):224-231. PubMed ID: 38484868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison between tafamidis and liver transplantation as first-line therapy for hereditary transthyretin amyloidosis.
    Socie P; Benmalek A; Cauquil C; Piekarski E; Kounis I; Eliahou L; Rousseau A; Rouzet F; Echaniz-Laguna A; Samuel D; Adams D; Slama MS; Algalarrondo V
    Amyloid; 2023 Sep; 30(3):303-312. PubMed ID: 36795029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transthyretin Variant Amyloidosis with a TTR A97D (p.A117D) Mutation Manifesting Remarkable Asymmetric Neuropathy.
    Ikeda K; Yamamoto D; Usui K; Takeuchi H; Oka N; Katoh N; Yazaki M; Kametani F; Nishino I; Hisahara S
    Intern Med; 2023 Aug; 62(15):2261-2266. PubMed ID: 36543209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort study.
    Qarni TN; Jones FJS; Drachman B; Khella S; Pieretti J; Bustamante NS; Karam C
    Orphanet J Rare Dis; 2024 May; 19(1):191. PubMed ID: 38720335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma.
    Nelson LT; Paxman RJ; Xu J; Webb B; Powers ET; Kelly JW
    Amyloid; 2021 Mar; 28(1):24-29. PubMed ID: 32811187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
    Sekijima Y
    J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three patients of transthyretin amyloidosis in a Japanese family with amyloidogenic transthyretin Thr49Ser (p.Thr69Ser) variant.
    Ikura H; Kitakata H; Endo J; Moriyama H; Sano M; Tsujikawa H; Sawano M; Masuda T; Ohki T; Ueda M; Kosaki K; Fukuda K
    Eur J Med Genet; 2022 Mar; 65(3):104451. PubMed ID: 35149236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hereditary transthyretin-related amyloidosis.
    Finsterer J; Iglseder S; Wanschitz J; Topakian R; Löscher WN; Grisold W
    Acta Neurol Scand; 2019 Feb; 139(2):92-105. PubMed ID: 30295933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation.
    Schmidt HH; Wixner J; Planté-Bordeneuve V; Muñoz-Beamud F; Lladó L; Gillmore JD; Mazzeo A; Li X; Arum S; Jay PY; Adams D;
    Am J Transplant; 2022 Jun; 22(6):1646-1657. PubMed ID: 35213769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease-Modifying Drugs Extend Survival in Hereditary Transthyretin Amyloid Polyneuropathy.
    Ueda M; Misumi Y; Nomura T; Tasaki M; Yamakawa S; Obayashi K; Yamashita T; Ando Y
    Ann Neurol; 2024 Feb; 95(2):230-236. PubMed ID: 38053464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis.
    Carroll A; Dyck PJ; de Carvalho M; Kennerson M; Reilly MM; Kiernan MC; Vucic S
    J Neurol Neurosurg Psychiatry; 2022 Jun; 93(6):668-678. PubMed ID: 35256455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The neuropathy in hereditary transthyretin amyloidosis: A narrative review.
    Tozza S; Severi D; Spina E; Iovino A; Aruta F; Ruggiero L; Dubbioso R; Iodice R; Nolano M; Manganelli F
    J Peripher Nerv Syst; 2021 Jun; 26(2):155-159. PubMed ID: 33960565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease.
    Adams D; Koike H; Slama M; Coelho T
    Nat Rev Neurol; 2019 Jul; 15(7):387-404. PubMed ID: 31209302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Neurological manifestations of ATTR amyloidosis].
    Pernice HF; Hahn K
    Inn Med (Heidelb); 2023 Sep; 64(9):848-854. PubMed ID: 37555967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A natural history analysis of asymptomatic
    Coelho T; Conceição I; Waddington-Cruz M; Keohane D; Sultan MB; Chapman D; Amass L;
    Amyloid; 2022 Dec; 29(4):228-236. PubMed ID: 35730447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings.
    Maia LF; Magalhães R; Freitas J; Taipa R; Pires MM; Osório H; Dias D; Pessegueiro H; Correia M; Coelho T
    J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):159-67. PubMed ID: 25091367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen.
    Coelho T; Waddington Cruz M; Chao CC; Parman Y; Wixner J; Weiler M; Barroso FA; Dasgupta NR; Jung SW; Schneider E; Viney NJ; Dyck PJB; Ando Y; Gillmore JD; Khella S; Gertz MA; Obici L; Berk JL
    Neurol Ther; 2023 Feb; 12(1):267-287. PubMed ID: 36525140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent progress in the understanding and treatment of transthyretin amyloidosis.
    Sekijima Y
    J Clin Pharm Ther; 2014 Jun; 39(3):225-33. PubMed ID: 24749898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug and Gene Therapy for Treating Variant Transthyretin Amyloidosis (ATTRv) Neuropathy.
    Dardiotis E; Kyriakides T
    Curr Neuropharmacol; 2023; 21(3):471-481. PubMed ID: 36366846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.